Back to discover

Protein / target

Interleukin-1 receptor-like 1

Encoded byIL1RL1Q01638Homo sapiensSwiss-Prot
UniProt: Q01638Ensembl: ENSG00000115602HGNC: HGNC:5998NCBI Gene: 9173
Clinical-stage
Therapeutic maturity
1
Clinical candidates
Antibody-tractable
Druggability
Advanced Clinical
1
Research papers

Protein at a glance

Biological role

NAD+ nucleosidase activity, cyclic ADP-ribose generating

Strongest disease association

Asthma

Via encoding gene IL1RL1 · Genetic evidence · score 0.91

Therapeutic position

Clinically advancing target

Antibodies

Research activity

Emerging research

1 papers · latest 2020

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Receptor for interleukin-33 (IL-33) which plays crucial roles in innate and adaptive immunity, contributing to tissue homeostasis and responses to environmental stresses together with coreceptor IL1RAP.

View complete UniProt function annotation

Receptor for interleukin-33 (IL-33) which plays crucial roles in innate and adaptive immunity, contributing to tissue homeostasis and responses to environmental stresses together with coreceptor IL1RAP (PubMed:35238669). Its stimulation recruits MYD88, IRAK1, IRAK4, and TRAF6, followed by phosphorylation of MAPK3/ERK1 and/or MAPK1/ERK2, MAPK14, and MAPK8. Possibly involved in helper T-cell function (Probable) (PubMed:16286016). Upon tissue injury, induces UCP2-dependent mitochondrial rewiring that attenuates the generation of reactive oxygen species and preserves the integrity of Krebs cycle required for persistent production of itaconate and subsequent GATA3-dependent differentiation of inflammation-resolving alternatively activated macrophages (By similarity)

Subcellular location

Cell membraneSecreted
Domains and Gene Ontology detail (24)

Domains & features

Ig-like C2-type 1Ig-like C2-type 2Ig-like C2-type 3TIR

Gene Ontology

  • Ccell surface
  • Cexternal side of plasma membrane
  • Cextracellular region
  • Cplasma membrane
  • Fcytokine receptor activity
  • Finterleukin-1 receptor activity
  • Finterleukin-33 binding
  • Finterleukin-33 receptor activity
  • FNAD+ nucleosidase activity, cyclic ADP-ribose generating
  • Pimmune response
  • Pinflammatory response
  • Pinterleukin-33-mediated signaling pathway

556 aa · 63 kDa · 4 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Immune signallingUniProt · GO
View supporting evidence

Immune signalling

  • ·Receptor for interleukin-33 (IL-33) which plays crucial roles in innate and adaptive imm…
  • ·cytokine receptor activity
  • ·interleukin-1 receptor activity
  • ·interleukin-33 binding

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene IL1RL1

Gene-level evidence surfaced through the gene IL1RL1that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Asthma
0.93Well supported

Genetic evidence dominant · Open Targets 0.59

Hypersensitivity
0.85Well supported

Genetic evidence dominant · Open Targets 0.52

Rhinitis, Allergic
0.85Well supported

Genetic evidence dominant · Open Targets 0.52

Childhood onset asthma
0.83Well supported

Genetic evidence dominant · Open Targets 0.50

Respiratory Tract Diseases
0.81Well supported

Genetic evidence dominant · Open Targets 0.49

View evidence synthesis (5)
AsthmaWell supported
0.93
agreement 0.82–1.00
Genetic78%Literature12%Clinical10%

Open Targets aggregate 0.59 · 3 independent evidence families

HypersensitivityWell supported
0.85
agreement 0.71–0.99
Genetic96%Literature4%

Open Targets aggregate 0.52 · 2 independent evidence families

Rhinitis, AllergicWell supported
0.85
agreement 0.71–0.99
Genetic95%Literature5%

Open Targets aggregate 0.52 · 2 independent evidence families

Childhood onset asthmaWell supported
0.83
agreement 0.69–0.97
Genetic98%Literature2%

Open Targets aggregate 0.50 · 2 independent evidence families

Respiratory Tract DiseasesWell supported
0.81
agreement 0.67–0.95
Genetic99%Literature1%

Open Targets aggregate 0.49 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Asthma0.59
Hypersensitivity0.52
Rhinitis, Allergic0.52
Childhood onset asthma0.50
Respiratory Tract Diseases0.49
Pulmonary Disease, Chronic Obstructive0.45

Drug development

1 compounds recorded · 1 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines.

View all recorded compounds (1)
ASTEGOLIMABPhase 3

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Antibodies — Strong

Advanced Clinical and UniProt loc high conf support this modality.

Protein degraders — Emerging

Feasibility evidence (uniprot ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (7)
AB · Advanced ClinicalAB · UniProt loc high confAB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMMAB · Human Protein Atlas locPR · UniProt Ubiquitination

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2020

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals.569 cites

Folkersen L · Nature metabolism · 2020

Recent

Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals.

Folkersen L · Nature metabolism · 2020

Europe PMC papers linked directly to this protein.